cnl_21

Epac - Associazione Onlus

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Portale Epatite e malattie del fegato

Malattie autoimmuni

Fai una donazione

Sostieni EpaC Onlus

Newsletter EpaC

Aggiornati via email. Iscriviti

Notiziario Epac

Periodico cartaceo. Iscriviti

Sangue Infetto

Visita il sito - legge 210/92

News nuovi farmaci in Inglese

Merck’s Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection

23/04/2014

AbbVie to Present Detailed Phase III Results from SAPPHIRE-I and SAPPHIRE-II Studies in Chronic Hepatitis C Patients at the 2014 International Liver Congress™

23/04/2014

AbbVie to Present Late-Breaking Results from TURQUOISE-II Study in Chronic Hepatitis C Patients with Cirrhosis at the 2014 International Liver Congress™

23/04/2014

Gilead’s Sovaldi® Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease

23/04/2014

AbbVie to Present Detailed Phase III Results from SAPPHIRE-I and SAPPHIRE-II Studies in Chronic Hepatitis C Patients at the 2014 International Liver Congress™

23/04/2014

Bristol-Myers Squibb Presents Phase III Data Demonstrating that Investigational All-oral Daclatasvir and Asunaprevir Therapy Achieved SVR12 Rates of up to 90% Among Broad Range of Genotype 1b Hepatitis C Patients

23/04/2014

Vertex Announces Sustained Viral Response Rate (SVR4) Data from All-Oral Study of VX-135 in Combination with Daclatasvir in Hepatitis C

31/01/2014

Antisense therapy for hepatitis C virus infection

31/01/2014

AbbVie Completa il più Vasto Programma Fase III per Terapia Completamente Orale Senza Interferone per il Trattamento di Epatite C Genotipo 1

31/01/2014

Regimen-Faldaprevir+Deleobuvir+PPI668

31/01/2014

BMS Regime orale per HCV senza interferone e senza ribavirina

31/01/2014

FDA Advisory Committee Recommends Approval of Simeprevir for Combination Treatment of Genotype 1 Chronic Hepatitis C in Adult Patients

31/01/2014

Simeprivir presentation at FDA

31/01/2014

FDA ADVISORY COMMITTEE SUPPORTS APPROVAL OF GILEAD’S SOFOSBUVIR FOR CHRONIC HEPATITIS C INFECTION

31/01/2014

Sofosfubir presentation at FDA

31/01/2014

Risultati provvisori della coorte 2 dello studio COSMOS per la valutazione di Simeprevir e Sofosbuvir in pazienti HCV con valori METAVIR F3-F4

31/01/2014

SVR con Daclatasvir più Sofosbuvir ± Ribavirina (RBV) in Pazienti HCV di Genotipo 1 con precedenti fallimenti terapeutici con Telaprevir (TVR) o Boceprevir (BOC)

31/01/2014

All-Oral Therapy With Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment-Experienced Genotype 2/3 HCV-Infected Patients: Results of the Phase 3 FUSION Trial

31/01/2014

FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAÏVE PATIENTS

03/05/2013

Interim Analysis of an Interferon (IFN)- and Ribavirin (RBV)-Free Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 in Treatment-Naive, Hepatitis C Virus Genotype 1-Infected Patients

03/05/2013

Pagina: 1 2 3 4 5

© Copyright 2015 - Associazione EpaC Onlus - C.F. 97375600158

Via Col. Tommaso Masala, 42
C/O Parco Altamira - 00148 Roma

Tel. 06.60200566 | Fax 06.60209056
Orari ufficio: 9.00-12.00 e 14.00-17.00

Via Luigi Cadorna, 17/A
20871 Vimercate Monza e Brianza

Tel. 0396083527 | Fax 039 6611523
Orari ufficio: 9.00-12.00 e 14.00-17.00

ACE - Alleanza Contro Epatiti World Hepatitis Alliance ELPA - European Liver Patients Associations